Fullerton Fund Management CO Ltd. Bei Gene, Ltd. Transaction History

Fullerton Fund Management CO Ltd.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$189.18 - $286.44 $747,261 - $1.13 Million	-3,950 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$123.9 - $195.41 $10,531 - $16,609	-85 Reduced 2.11%	3,950 $744,000
Q1 2020 May 15, 2020	SELL	$121.84 - $173.19 $319,830 - $454,623	-2,625 Reduced 39.41%	4,035 $497,000
Q4 2019 Feb 14, 2020	SELL	$115.78 - $208.34 $33,460 - $60,210	-289 Reduced 4.16%	6,660 $1.1 Million
Q3 2019 Nov 14, 2019	BUY	$120.61 - $148.29 $120,730 - $148,438	1,001 Added 16.83%	6,949 $851,000
Q2 2019 Aug 14, 2019	SELL	$113.99 - $146.86 $18,124 - $23,350	-159 Reduced 2.6%	5,948 $737,000
Q1 2019 May 15, 2019	BUY	$122.82 - $151.83 $1,719 - $2,125	14 Added 0.23%	6,107 $806,000
Q4 2018 Feb 14, 2019	BUY	$107.01 - $175.15 $652,011 - $1.07 Million	6,093 New	6,093 $855,000

252

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.6B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Fullerton Fund Management CO Ltd., based on Form 13F filings with the SEC.

Stay updated on Fullerton Fund Management CO Ltd. with notifications on news.